-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Upgrades Regeneron Pharmaceuticals to Buy, Raises Price Target to $978

Benzinga·10/15/2026 21:23:05
语音播报
UBS analyst Trung Huynh upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) from Neutral to Buy and raises the price target from $660 to $978.